AI Accelerates In Drug Discovery
Executive Summary
Artificial Intelligence has been hyped as a game changer in drug discovery for the last five years. How far has it come, and how far can it go? In Vivo talks to some of the key players that are creating and shaping the future of the industry.
You may also be interested in...
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
Fueled By Connections: Making It Happen In Rare Disease
Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.
Pushing Forward: Venture Capitalist Priorities To Accelerate European Biotech
Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.